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Leukotriene C4 is a potent constrictor of smooth muscle in vitro 
and may induce coronary vasoconstriction in vivo. To study 
leukotriene C4 release by neutrophils in patients with coronary 
artery disease, neutrophils were separated from blood samples 
taken from the coronary sinus and aorta in 20 patients with stable 
exertional angina and angiographically documented coronary 
artery narrowings (group I). Eight patients with normal coronary 
arteries were also studied (group II). 
To assess leukotriene C4 generation, neutrophils were incu-
bated with calcium ionophore A 23187 (0.25 pM) and the super-
natants obtained after centrifugation were analyzed for leukotri-
ene C4 by radioimmunoassay. 
Patients in group I had a significantly lower release of leuko-
triene C4 from neutrophils separated from the coronary sinus 
blood than from those separated from aortic blood (4.33 ± 0.69 
versus 5.92 ± 0.54 ng/ml, p < 0.025), whereas patients in group 
II had a similar release of leukotriene C4 by the neutrophils 
Neutrophil function is enhanced in patients with ischemic 
heart disease (1). Once activated, these leukocytes may 
release a variety of mediators such as proteolytic enzymes, 
oxygen free radicals and leukotrienes (2). The latter sub-
stances are 5-lipooxygenase metabolites of arachidonic acid 
with potent action on many organs and functions, including 
the cardiovascular system (3). In particular, leukotriene C4 is 
a potent constrictor of smooth muscle in several different 
preparations and induces coronary vasoconstriction in vivo 
(4). Because of these properties, leukotriene C4 has been 
implicated in the pathogenesis of coronary spasm, stasis of 
flow and intravascular thrombosis (5). The purpose of this 
study was to determine leukotriene C4 generation by stimu-
lated neutrophils in patients with stable angina and angio-
graphically documented coronary artery disease as com-
pared with control subjects with a normal coronary tree. 
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separated from coronary sinus blood and from aortic blood (6.0 ± 
0.72 versus 6.4 ± 0.66 ng/ml, p = NS). Moreover, in group I 
patients, a significant correlation was found (p < 0.01) between 
the extent of coronary artery disease (expressed by the Leaman 
coronary score) and the percent reduction in leukotriene C4 
released from neutrophiIs separated from coronary sinus blood as 
compared with leukotriene C4 produced by neutrophils separated 
from aortic blood. 
These data show that neutrophils from patients with coronary 
artery disease have a reduced ability to produce leukotriene C4 
after stimulation by calcium ionophore A 23187. The release of 
leukotriene C4 from neutrophils passing through a diseased cor-
onary tree may contribute to the development of the inappropriate 
vasoconstriction associated with the endothelial dysfunction of 
atherosclerotic coronary vessels. 
(J Am Coil CardioI1991;17:1125-8) 
Methods 
Study patients. Twenty-eight patients who underwent 
diagnostic coronary arteriography were studied. All patients 
gave written informed consent and the protocol was ap-
proved by the hospital Ethics Committee. Twenty patients 
(group I) had a clinical diagnosis of exertional angina and a 
positive exercise test, defined as the development of ST 
segment depression 2:: I mm. All patients were men with a 
mean age of 53 years (range 30 to 67). Of the remaining eight 
patients (group 11), seven complained of chest pain but had a 
negative exercise test, and one had moderate mitral valve 
prolapse with mitral regurgitation. There were five men and 
three women with a mean age of 52 years (range 42 to 63). 
At the time of the study, no patient had congestive heart 
failure or an acute infective disease. Cardioactive drugs, which 
included nitrates, nifedipine and beta-adrenergic blockers in 
group I patients, were progressively tapered and finally discon-
tinued 2::24 h before the study (72 h for beta-blockers). No 
patient was taking platelet antiaggregating agents. Significant 
coronary artery disease was defined as > 50% narrowing in the 
luminal diameter of any individual coronary vessel. For each 
patient, a coronary score was computed according to the 
method proposed by Leaman et al. (6). 
0735-1097/91/$3.50 
1126 DE SERVI ET AL. 
LEUKOTRIENE C4 RELEASE BY NEUTROPHILS 
Study protocol. Patients were studied in the fasting state 
after premedication with diazepam (10 mg). At the beginning 
of the procedure, a no. 8 Lehman catheter was advanced 
from the brachial artery and placed in the ascending aorta 
and a no. 7 Gorlin catheter was inserted in an antecubital 
vein and placed in the coronary sinus. Simultaneous sam-
pling (15 ml of heparinized blood) was obtained from the 
aorta and coronary sinus before the injection of contrast 
medium. 
Separation of neutrophils. Dextran 6% (20 mI) was added 
to blood samples that were immediately placed in a carbon 
dioxide incubator at 37°C. The polymorphonuclear leuko-
cytes were purified by means of the Isopaque-Ficoll system 
(7). Contaminating erythrocytes in the neutrophil fraction 
were removed by lysis with 0.75% ammonium chloride 
solution containing Tris hydrochloride buffer (20 mM, final 
pH 7.4) and 0.25% autologous plasma. The purity of the cell 
fractions was 96 ± 2% neutrophils. Granulocytes were 
resuspended in sodium chloride (145 mM) containing 
HEPES (10 mM), potassium hydroxide (5 mM), calcium 
chloride (1.3 mM) and magnesium chloride (1.2 mM), 
pH 7.45 (HEPES buffer). Cell viability was >95% as mea-
sured by trypan blue exclusion or release of the cytoplas-
matic enzyme lactic dehydrogenase. Only the platelet free 
neutrophil suspensions were tested. Cells were evaluated 
within 30 min of the separation procedure. 
Granulocyte leukotriene C4 generation. To assess leuko-
triene C4 generation, neutrophils (3 x 106/mI) were incu-
bated at 37°C for 15 min in a shaking water bath, with 
calcium ionophore A 23187 (0.25 pM), a concentration at 
which maximalleukotriene C4 production occurs. The reac-
tion was stopped by placing the tube in ice for 5 min and 
subsequently adding cold methanol (0.5 mI). Suspensions 
were centrifuged at 11,000 g for 5 min at 4°C and superna-
tants were collected and stored at -70°C. Supernatants were 
analyzed for leukotriene C4 levels by radioimmunoassay 
(New England Nuclear Chemicals). 
From these values, we subtracted the levels of leukotri-
ene C4 obtained in a similar way in the control experiments, 
in which the same quantity of phosphate buffer saline 
solution was added to granulocyte suspensions. The selec-
tivity of the assay is high, with low cross-reactivity with 
other leukotrienes (B4 0.03%, D4 11.6%, E4 3.3%). 
Statistical analysis. All data are expressed as mean values 
± SEM. Student's t test for paired data was used to compare 
mean values calculated from continuous data. The correla-
tion between the Leaman coronary score and the percent 
reduction in leukotriene C4 generation in coronary sinus 
blood compared with aortic blood was calculated by the 
Spearman rank correlation coefficient. 
Results 
Clinical and angiographic findings. All 20 patients in 
group I had significant coronary artery disease, involving 
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Figure 1. Mean values ± SE of leukotriene C4 (LTC4) release by 
stimulated neutrophils separated from blood samples taken from the 
coronary sinus and aorta in 20 patients (PTS) with coronary artery 
disease (CAD) and 8 control subjects with normal coronary arteries. 
ejection fraction was 0.59 (range 0.38 to 0.77). All eight 
patients in group II had normal coronary arteries and the 
mean ejection fraction was 0.58 (range 0.52 to 0.80). 
Leukotriene C4 generation by stimulated neutrophils (Fig. 
1 and 2). Mean leukocyte count was 7.56 ± 0.84 in group I 
and 7.13 ± 1.12 in group II (p = NS). Group I patients had 
a significantly lower release of leukotriene C4 from neutro-
phils separated from coronary sinus blood than from those 
separated from aortic blood (4.33 ± 0.69 versus 5.92 ± 
0.54 ng/ml, p < 0.025). Group II patients had a similar 
release of leukotriene C4 by neutrophils separated from 
coronary sinus blood and from aortic blood (6.0 ± 0.72 
versus 6.4 ± 0.66 ng/ml, p = NS) (Fig. 1). In group I 
patients, a significant correlation was found between the 
Leaman coronary score and the percent reduction in leuko-
triene C4 release from neutrophils separated from coronary 
sinus blood compared with leukotriene C4 release from 
neutrophils separated from aortic blood (r = 0.71, p < 0.01) 
(Fig. 2). 
Figure 2. In the 20 patients with coronary artery disease, a signifi-
cant linear correlation was found between the Leaman coronary 
score and the percent reduction in leukotriene C4 (LTC4) release by 
stimulated neutrophils separated from coronary sinus blood com-
pared with aortic blood. 
Rs=O.71 p<o.o I 
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Discussion 
Biosynthesis and effects of leukotriene C4. Arachidonic 
acid, a component of the membrane phospholipids of mam-
malian cells, is rapidly metabolized to a variety of com-
pounds, depending on the enzyme present in the tissue. In 
platelets, arachidonic acid is metabolized to thromboxane A2 
and prostaglandins by the cyclooxygenase pathway, 
whereas in leukocytes, arachidonic acid is preferentially 
metabolized to leukotrienes through the lipoxygenase path-
way (7-9). Leukotriene C4 and its metabolites leukotriene D4 
and leukotriene E4 were originally described as "slow-
reacting substances of anaphylaxis" (10) and are now col-
lectively referred to as "peptide leukotrienes" (11). The 
generation and release of such compounds have been dem-
onstrated in human neutrophils, eosinophils, mast cells, 
macrophages and monocytes. Under certain conditions, 
endothelial cells and smooth muscle cells may also synthe-
size leukotriene C4 by conversion of exogenous leukotriene 
A4 (12). 
Peptide leukotrienes are very potent "proinflammatory" 
mediators that are able to contract smooth muscle cells from 
bronchus and gastrointestinal tissues, induce vasoconstric-
tion and increase endothelial cell permeability (3). Vasocon-
striction has been demonstrated by the ability of leukotriene 
C4 and leukotriene D4 to increase systemic vascular resis-
tance in the rat and diminish coronary blood flow in the 
isolated guinea pig heart (13). Ezra et al. (5) injected increas-
ing doses of leukotriene C4, D4 and E4 into the left anterior 
descending artery of eight open chest domestic pigs. A 
significant dose-related reduction in coronary blood flow 
was observed, frequently accompanied by electrocardio-
graphic signs of myocardial ischemia and an increase in left 
ventricular filling pressure. Recently, Marone et al. (11) 
studied the effects of the intravenous injection of a small 
dose (3 nmol) of leukotriene D4 in patients with normal 
coronary arteries. The authors found a progressive increase 
in coronary vascular resistance that peaked 15 min after 
injection with return to baseline values at 20 min. Such 
increase was associated with greater myocardial oxygen 
extraction, whereas myocardial oxygen consumption did not 
change. 
The vasoconstrictor effect of leukotriene C4 on coronary 
arteries is synergistic with that induced by platelet-released 
thromboxane A2 because experimental data (8) show that the 
decrease in coronary blood flow produced by the combina-
tion of both substances is greater than the sum of changes 
caused by the two eicosanoids administered separately. 
Although the recognition of these properties led to the 
hypothesis that leukotrienes could be implicated in vasospas-
tic disorders, a role for these substances in the pathogenesis 
of myocardial ischemia has never been demonstrated. One 
main difficulty is related to the short half-life of leukotrienes 
in the blood circulation, thus precluding meaningful deter-
minations in blood plasma under most conditions (14,15). 
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Transcardiac generation of leukotriene C4 by stimulated 
neutrophils. In this study, neutrophils were separated from 
blood samples taken from patients with coronary artery 
disease and subjects with normal coronary arteries. After 
stimulation with calcium ionophore A 23187, supernatants 
were analyzed for leukotriene C4 by radioimmunoassay. In 
each patient, two measurements were obtained, one after 
stimulation of neutrophils separated from blood samples 
taken from the aorta and the other after stimulation of 
neutrophils collected from the coronary sinus, to assess 
whether the passage through the coronary circulation would 
modify the response of leukocytes to the same stimulus. Our 
results show that in patients with coronary artery disease, 
neutrophils separated from coronary sinus blood released a 
smaller amount of leukotriene C4 than did neutrophils iso-
lated from aortic blood, whereas no difference was found in 
the subjects with normal coronary vessels. Moreover, a 
significant correlation was found between the extent of 
coronary artery disease and the percent reduction in leuko-
triene C4 generation by neutrophils isolated from coronary 
sinus compared with aortic blood. One explanation is that 
neutrophils can be activated during their passage over the 
atheromatous plaques of coronary arteries and that they 
generate leukotriene C4. Prior activation in the coronary 
arteries may account for the lower release of leukotriene C4 
by neutrophils separated from the coronary sinus blood of 
patients with coronary artery disease. Recent data (1) sug-
gest that neutrophils have increased activity in patients with 
ischemic heart disease. The basis for such enhanced function 
may relate to complement activation because the terminal 
C5b-9 complement complex has been localized in coronary 
fibrous plaques, suggesting complement activation in athero-
sclerotic arterial tissues (16). 
Alternative explanation for the reduced release of leukotri-
ene C4 by neutrophils collected from coronary sinus blood 
from patients with coronary artery disease. Neutrophils may 
transfer leukotriene A4, the immediate precursor of leuko-
triene C4, to endothelial cells. There is considerable evi-
dence (12) that vascular cells are unable to generate leuko-
triene A4 (and hence leukotriene C4) from arachidonic acid, 
but they are able to synthesize leukotriene C4 from exoge-
nous sources of leukotriene A4. Although endothelial and 
smooth muscle cells may be important contributors to the 
total production ofleukotriene C4 (17,18), they must interact 
with other cell types, such as neutrophils, that serve as a 
source of leukotriene A4 (12). It is known that injured 
endothelium promotes neutrophil adhesion to the vessel wall 
(19) and exposure of endothelial receptors for C3b has been 
reported (20) after endothelial injury. These receptors could 
act to localize complement to the vessel wall and thereby 
increase neutrophil adherence through similar receptors 
present on the neutrophils. As a consequence of the close 
interactions between damaged endothelium and neutrophils, 
these leukocytes could transfer the metabolic precursor 
leukotriene A4 to the vascular cells. As a result, neutrophils 
separated from coronary sinus blood of patients with athero-
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sclerotic involvement of coronary vessels would release 
smaller quantities of leukotriene C4 after stimulation by 
calcium ionophore. 
Implications. Our data show a reduced ability of neutro-
phils after stimulation by calcium ionophore to release 
leukotriene C4 once they have passed through a diseased 
coronary tree. In contrast to endothelium-dependent relax-
ation, endothelium-dependent contraction becomes promi-
nent under certain conditions, including atherosclerosis, 
favoring the occurrence of vasoconstriction (21). Chronic 
endothelial injury and coronary stenosis lead to the accumu-
lation of platelets and white blood cells that can release 
potent vasoconstrictor mediators (22). Leukotriene C4 pro-
duction by neutrophils may contribute to the development of 
the inappropriate vasoconstriction that occurs as a result of 
the endothelial dysfunction associated with the atheroscle-
rotic involvement of coronary vessels. 
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